Search For "fabiflu"
Glenmark concludes post marketing surveillance (PMS) study on Favipiravir
Updated : 4 years, 8 months ago IST
Mumbai (Maharashtra) [India], September 15 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India.
Read More
Glenmark's post-marketing surveillance shows no safety concerns on use of
Updated : 4 years, 8 months ago IST
New Delhi [India], September 15 (ANI): The Glenmark Pharmaceuticals' post-marketing surveillance (PMS) study has shown no safety concerns with the use of Favipiravir (FabiFlu®[?]) in India for COVID-19 infection.
Read More
Glenmark releases interim data from PMS Study on Favipiravir (FabiFlu®
Updated : 4 years, 11 months ago IST
Mumbai (Maharashtra) [India], June 9 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India.
Read More
Ready to face court's decision, says Gautam Gambhir on Fabiflu hoarding ca
Updated : 4 years, 11 months ago IST
New Delhi [India], June 4 (ANI): Bharatiya Janata Party (BJP) leader Gautam Gambhir on Friday said that he is ready to face the court's decision in the matter relating to the hoarding of anti-viral drug Fabiflu amid the COVID-19 pandemic.
Read More
Activist Yogita Bhayana moves HC seeking direction to Kwality Pharmaceutic
Updated : 5 years ago IST
New Delhi [India], May 6 (ANI): Social Activist Yogita Bhayana moved the Delhi High Court seeking direction to Kwality Pharmaceuticals Limited to supply the available units of the Remdesivir and further directed it to use the full capacity to manufacture/produce the Remdesivir and supply the
Read More
Group of lawyers write to CJI over black marketing of oxygen, lifesaving d
Updated : 5 years, 1 month ago IST
New Delhi [India], April 26 (ANI): A group of lawyers, including the founder of Justice For Rights Foundation, Satyam Singh Rajput, have written an open letter to newly-appointed Chief Justice of India (CJI) N V Ramana and have requested him to look into the black marketing of oxygen and Rem
Read More
After facing flak over distribution of Fabiflu, Gautam Gambhir says proud
Updated : 5 years, 1 month ago IST
New Delhi [India], April 22 (ANI): After receiving flak for giving out 'free Flabiflu' in his parliamentary constituency East Delhi, BJP MP Gautam Gambhir on Thursday asked if a few strips of Fabiflu he obtained is causing its shortage and said he is proud to save somebody's life in this pan
Read More
COVID-19: BJP MP Gautam Gambhir offers free 'Fabiflu' at his East Delhi of
Updated : 5 years, 1 month ago IST
New Delhi [India], April 22 (ANI): Bharatiya Janata Party (BJP) MP Gautam Gambhir has announced free distribution of antiviral drug 'Fabiflu' in his parliamentary constituency East Delhi amid an acute shortage of Covid-19 medicines in the national capital.
Read More
Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce th
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India] Aug 6 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India.
Read More
Glenmark introduces higher strength of FabiFlu to reduce pill burden of Co
Updated : 5 years, 9 months ago IST
Mumbai (Maharashtra) [India], Aug 6 (ANI): Glenmark Pharmaceuticals will introduce a 400 mg version of oral anti-viral FabiFlu for the treatment of mild to moderate Covid-19 in India.
Read More
Glenmark responds to DCGI letter seeking clarification on Fabiflu
Updated : 5 years, 10 months ago IST
Mumbai (Maharashtra) [India] July 21 (ANI/PRNewswire): In response to the DCGI letter seeking clarification on FabiFlu, Glenmark Pharmaceuticals Ltd, a research-led, integrated global pharmaceutical company, has responded back. Please click the link below, to access the response letter.
Read More
DCGI seeks clarification from Glenmark on its anti-viral favipiravir for u
Updated : 5 years, 10 months ago IST
New Delhi [India], July 19 (ANI): The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
Read More